. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005

Table 2.

Concentrations of test compounds for the concentration–response curve and the CIx experiments.

Test Compound	Tested Concentration (µM)		Human-Relevant Concentration (µM)
Test Compound	Concentration-Response	CIx	Human-Relevant Concentration (µM)
BOS	0; 0.015; 0.075; 0.15; 0.75; 1.5; 7.5; 15; 75	0; 0.15; 1.5; 7.5; 75	7.5 *
CyA	0; 0.01; 0.05; 0.1; 0.5; 1; 2.5; 5; 10; 25	0; 0.01; 0.05; 0.5; 5	0.8 *
MAC	0; 0.005; 0.05; 0.25; 0.5; 1; 2.5; 5; 10	0; 0.005; 0.5; 5; 10	0.5 *
PQ	0; 0.02; 0.2; 1; 2; 10; 20; 80; 200; 500	0; 0.2; 1; 2; 10	2.0 ^#
TAR	0; 0.0001; 0.001; 0.01; 0.1; 1; 10; 100; 1000	0; 0.0001; 0.01; 10; 1000	0.01 ^$
TRI	0; 0.01; 0.1; 1; 10; 100; 1000	0; 0.1; 1; 10; 100	10 ^&

* Cmax_total [35,36,37], ^# serum level in patient with cholestasis [22], ^$ estimated human exposure [38], ^& maximum estimated steady-state concentration [34]. BOS—bosentan; CIx—cholestatic index; CyA—cyclosporine-A; MAC—macitentan; PQ—paraquat; TAR—tartrazine; TRI—triclosan.